Correction to "MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model". . IUBMB Life 2026;78:e70134.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

. Correction to "MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model". IUBMB Life 2026;78:e70134.
PMID: 42852531